![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Pan-Genotypic Hepatitis C Treatment With Glecaprevir/Pibrentasvir Achieves Greatest Improvements in Quality-Adjusted Life-Years and Lifetime Risk Reductions in Liver-Related Morbidity and Mortality vs Standards of Care: A Cost-Utility Analysis
|
|
|
Reported by Jules Levin
American Association for the Study of Liver Diseases (AASLD) Congress, October 20-24, 2017, Washington, DC, USACONCLUSIONS
Sammy Saab1, Helene Parise2, Suchin Virabhak2, Scott Johnson2, Brett Pinsky3, Yuri Sanchez Gonzalez31David Geffen School of Medicine, UCLA, Los Angeles, CA; 2Medicus Economics, LLC, Boston, MA; 3Health Economics and Outcomes Research, AbbVie Inc., North Chicago, IL
![1027171](../images/102817/102817-5/1027171.gif)
![1027172](../images/102817/102817-5/1027172.gif)
![1027173](../images/102817/102817-5/1027173.gif)
![1027174](../images/102817/102817-5/1027174.gif)
![1027175](../images/102817/102817-5/1027175.gif)
![1027176](../images/102817/102817-5/1027176.gif)
![1027177](../images/102817/102817-5/1027177.gif)
![1027178](../images/102817/102817-5/1027178.gif)
![1027179](../images/102817/102817-5/1027179.gif)
![10271710](../images/102817/102817-5/10271710.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|